BOONTON, N.J., Dec. 5, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that the Company terminated its amended and restated exclusive worldwide license agreement and ...
This multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study will include an open label comparator arm of the Forsteo® injectable formulation. The primary ...
The European Commission on Tuesday gave Eli Lilly & Co. approval to market its Forsteo osteoporosis treatment, which already is on sale in the U.S. The injectable medication, which is also known by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback